NEW YORK (GenomeWeb News) — Emiliem and Invitrogen will screen Emiliem’s multi-kinase inhibitors under a partnership agreement, the companies said today.
The companies said they will use Invitrogen’s SelectScreen for kinase and P450 screening and cellular pathway profiling to study Emiliem’s cancer compounds.
The two-phase agreement calls for Invitrogen to confirm specificity and potency of Emiliem’s compounds, to study the effects of these compounds on biological pathways, and to use metabolizing liver enzymes to determine profiles of lead molecules.
The SelectScreen service uses enzyme collections and cell lines.
Financial terms of the agreement were not disclosed.